Modulation of oxidative stress-induced changes in hypertension and atherosclerosis by antioxidants

Experimental and Clinical Cardiology

Volumn 11, Issue 3, 2006, Pages 206-216

  Vasdev, Sudesh ^a   Gill, Vicki D ^a   Singal, Pawan K ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antioxidants; Atherosclerosis; Hypertension; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DIHYDROLIPOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; POLYPHENOL DERIVATIVE; PROTEIN; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID; THIOL GROUP; UBIDECARENONE;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG METABOLISM; DRUG OXIDATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MODULATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 33749638442     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (160)

1. Chakravarti RN, Kirshenbaum LA, Singal PK. Atherosclerosis: Its pathophysiology with special reference to lipid peroxidation. J Appl Cardiol 1991;6:91-112.
2. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med 1996;156:1952-6.
3. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-478.
4. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: Implications in hypertension. Histochem Cell Biol 2004;122:339-52.
5. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000;279:L1005-28.
6. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
7. 2+ /calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998;273:25804-8.
8. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111:1201-9.
9. Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal PK. Free radicals and the heart. J Pharmacol Toxicol Methods 1993;30:55-67.
10. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22:359-78.
11. World Health Organization. Global strategy on diet, physical activity and health. Chronic disease risk factors. (Version current at May 1, 2006).
12. Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of "syndrome X". Am J Hypertens 1993;6:123S-34S.
13. Taddei S, Ghiadoni L, Virdis D, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: Clinical significance and preventative non-pharmacological therapeutic strategies. Curr Pharmacol Design 2003;9:2385-402.
14. World Health Organization. Global strategy on diet, physical activity and health. Cardiovascular disease: Prevention and control. (Version current at May 1, 2006).
15. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-26.
16. Palinski W, Koschinsky T, Butler SW, et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995;15:571-82.
17. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
18. Tegos TJ, Kalodiki E, Sabetai MM, Nicolaides AN. The genesis of atherosclerosis and risk factors: A review. Angiology 2001;52:89-98.
19. Neutel JM. Why lowering blood pressure is not enough: The hypertension syndrome and the clinical context of cardiovascular risk reduction. Heart Dis 2000;2:370-4.
20. Pepine CJ, Handberg EM. The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors. Clin Cardiol 2001;24(Suppl 11):V1-5.
21. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;313:350-7.
22. DeFronzo R, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
23. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996;93:1809-17.
24. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003;88:2399-403.
25. Alexander MC, Lomanto M, Nasrin N, Ramaika C. Insulin stimulates glyceraldehyde-3-phosphate dehydrogenase gene expression through cis-acting DNA sequences. Proc Natl Acad Sci USA 1988;85:5092-6.
26. Thornalley PJ. Modification of the glyoxalase system in disease processes and prospects for therapeutic strategies. Biochem Soc Trans 1993;21:531-4.
27. Beisswenger PJ, Howell SK, Smith K, Szwergold B. Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Acta 2003;1637:98-106.
28. Morgan PE, Dean RT, Davies MJ. Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys 2002;403:259-69.
29. Chang KC, Paek KS, Kim HJ, Lee YS, Yabe-Nishimura C, Seo HG. Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. Mol Pharmacol 2002;61:1184-91.
30. Dargel R. Lipid peroxidation - A common pathogenetic mechanism? Exp Toxicol Pathol 1992;44:169-81.
31. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids 2003;25:275-81.
32. Zeng J, Davies MJ. Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol 2005;18:1232-41.
33. Nagaraj RH, Sarkar P, Mally A, Biemel KM, Lederer MO, Padayatti PS. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: Characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 2002;402:110-9.
34. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003;31:1423-5.
35. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685-94.
36. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003;25:283-92.
37. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-13.
38. Oya T, Hattori N, Mizuno Y, et al. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 1999;274:18492-502.
39. Nagai R, Hayashi CM, Xia L, Takeya M, Horiuchi S. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J Biol Chem 2002;277:48905-12.
40. Wang X, Desai K, Clausen JT, Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 2004;66:2315-21.
41. Wang X, Desai K, Chang T, Wu L. Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 2005;23:1565-73.
42. Stadtman TC. Selenium biochemistry. Annu Rev Biochem 1990;59:111-27.
43. Park YS, Koh YH, Takahashi M, et al. Identification of the binding site of methylglyoxal on glutathione peroxidase: Methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites Arg 184 and 185. Free Radic Res 2003;37:205-11.
44. Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 2002;39:809-14.
45. Farahmand F, Lou H, Singal PK. Oxidative stress in cardiovascular complications in diabetes. In: Pierce GN, Nagano M, Zahradka P, Dhalla NS, eds. Atherosclerosis, Hypertension and Diabetes. Boston: Kluwer Academic Publishers, 2003:427-37.
46. Hangaishi M, Taguchi J, Miyata T, et al. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun 1998;248:285-92.
47. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol 2000;278:F676-83.
48. Chang T, Wang R, Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic Biol Med 2005;38:286-93.
49. Morgan PE, Dean R, Davies MJ. Inhibition of glyceraldehyde-3-phosphate dehydrogenase by peptide and protein peroxides generated by singlet oxygen attack. Eur J Biochem 2002;269:1916-25.
50. Tsuchiya Y, Yamaguchi M, Chikuma T, Hojo H. Degradation of glyceraldehyde-3-phosphate dehydrogenase triggered by 4-hydroxy-2-nonenal and 4-hydroxy-2-hexenal. Arch Biochem Biophys 2005;438:217-22.
51. Brooks BR, Klamerth OL. Interaction of DNA with bifunctional aldehydes. Eur J Biochem 1968;5:178-82.
52. Benedetti A, Comporti M, Esterbauer H. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim Biophys Acta 1980;620:281-96.
53. Wen Y, Killalea S, McGettigan P, Feely J. Lipid peroxidation and antioxidant vitamins C and E in hypertensive patients. Ir J Med Sci 1996;165:210-2.
54. Nyyssönen K, Parviainen MT, Salonen R, Tuomilehto J, Salonen JT. Vitamin C deficiency and risk of myocardial infarction: Prospective population study of men from eastern Finland. BMJ 1997;314:634-8.
55. Ness AR, Khaw KT, Bingham S, Day NE. Vitamin C status and blood pressure. J Hypertens 1996;14:503-8.
56. Kashyap MK, Yadav V, Sherawat BS, et al. Different antioxidants status, total antioxidant power and free radicals in essential hypertension. Mol Cell Biochem 2005;277:89-99.
57. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991;53(Suppl 1):326S-34S.
58. Yochum LA, Folsom AR, Kushi LH. Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. Am J Clin Nutr 2000;72:476-83.
59. Manning RD Jr, Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 2003;179:243-50.
60. Reaven PD, Witztum JL. Oxidized low density lipoproteins in atherogenesis: Role of dietary modification. Annu Rev Nutr 1996;16:51-71.
61. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J Am Coll Cardiol 2004;43:1731-7.
62. Wu D, Cederbaum AI. Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003;27:277-84.
63. 2+-ATPase of cardiac sarcoplasmic reticulum. Mol Cell Biochem 2003;248:41-7.
64. Viner RI, Williams TD, Schoneich C. Peroxynitrite modification of protein thiols: Oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase. Biochemistry 1999;38:12408-15.
65. Nakashima I, Takeda K, Kawamoto Y, Okuno Y, Kato M, Suzuki H. Redox control of catalytic activities of membrane-associated protein tyrosine kinases. Arch Biochem Biophys 2005;434:3-10.
66. Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol 1995;15:3892-903.
67. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005;97:967-74.
68. Suzuki YJ, Ford GD. Redox regulation of signal transduction in cardiac and smooth muscle. J Mol Cell Cardiol 1999;31:345-53.
69. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005;353:9-11. (Erratum in 2005;353:1869).
70. Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003;28:509-14.
71. Tabatabaie T, Floyd RA. Susceptibility of glutathione peroxidase and glutathione reductase to oxidative damage and the protective effect of spin trapping agents. Arch Biochem Biophys 1994;314:112-9.
72. Turi S, Friedman A, Bereczki C, et al. Oxidative stress in juvenile essential hypertension. J Hypertens 2003;21:145-52.
73. Kedziora-Kornatowska K, Czuczejko J, Pawluk H, et al. The markers of oxidative stress and activity of the antioxidant system in the blood of elderly patients with essential arterial hypertension. Cell Mol Biol Lett 2004;9:635-41.
74. Russo C, Olivieri O, Girelli D, et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens 1998;16:1267-71.
75. Chen PF, Tsai AL, Wu KK. Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity. J Biol Chem 1994;269:25062-6.
76. Shinozaki K, Kashiwagi A, Masada M, Okamura T. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord 2004;4:1-11.
77. Ma XL, Gao F, Nelson AH, et al. Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 2001;298:879-85.
78. Dickhout JG, Hossain GS, Pozza LM, Zhou J, Lhotak S, Austin RC. Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: Implications in atherogenesis. Arterioscler Thromb Vasc Biol 2005;25:2623-9.
79. Touyz RM. Recent advances in intracellular signalling in hypertension. Curr Opin Nephrol Hypertens 2003;12:165-74.
80. Ikemoto F, Song G, Tominaga M, Yamamoto K. Oxidation-induced increase in activity of angiotensin converting enzyme in the rat kidney. Biochem Biophys Res Commun 1988;153:1032-7.
81. Guzik TJ, Sadowski J, Guzik B, et al. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 2006;26:333-9.
82. Fortuno A, Olivan S, Beloqui O, et al. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004;22:2169-75.
83. Dixon LJ, Hughes SM, Rooney K, et al. Increased superoxide production in hypertensive patients with diabetes mellitus: Role of nitric oxide synthase. Am J Hypertens 2005;18:839-43.
84. 2 production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem 2001; 276:29251-6.
85. Schulman IH, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: Role in atherosclerosis and hypertension. J Hypertens 2006;24:S45-S50.
86. 2+ release from sarcoplasmic reticulum via an oxidation reaction. J Biol Chem 1989;264:21725-36.
87. Tabet F, Savoia C, Schiffrin EL Touyz RM. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004;44:200-8.
88. 2+-ATPase of vascular smooth muscle sarcoplasmic reticulum by reactive oxygen intermediates. Am J Physiol 1991;261:H568-74.
89. Bartlett RK, Bieber Urbauer RJ, Anbanandam A, Smallwood HS, Urbauer JL, Squier TC. Oxidation of Met144 and Met145 in calmodulin blocks calmodulin dependent activation of the plasma membrane Ca-ATPase. Biochemistry 2003;42:3231-8.
90. Gordeeva AV, Zvyagilskaya RA, Labas YA. Cross-talk between reactive oxygen species and calcium in living cells. Biochemistry (Mosc) 2003;68:1077-80.
91. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006;185:219-26.
92. Jiang F, Drummond GR, Dusting GJ. Suppression of oxidative stress in the endothelium and vascular wall. Endothelium 2004;11:79-88.
93. Chiu HC, Jeng JR, Shieh SM. Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease. Biochim Biophys Acta 1994;1225:200-8.
94. Lankin VZ, Lisina MO, Arzamastseva NE, et al. Oxidative stress in atherosclerosis and diabetes. Bull Exp Biol Med 2005;140:41-3.
95. Maggi E, Marchesi E, Ravetta V, Falaschi F, Finardi G, Bellomo G. Low-density lipoprotein oxidation in essential hypertension. J Hypertens 1993;11:1103-11.
96. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72.
97. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90.
98. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998;18:1617-24.
99. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-7.
100. Uzun H, Karter Y, Aydin S, et al. Oxidative stress in white coat hypertension; role of paraoxonase. J Hum Hypertens 2004;18:523-8.
101. Mancia G, Facchetti R, Bombelli M, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005;45:1072-7.
102. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:1545-50.
103. Stoclet JC, Chataigneau T, Ndiaye M, et al. Vascular protection by dietary polyphenols. Eur J Pharmacol 2004;500:299-313.
104. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148:e5.
105. Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003;90:317-21.
106. Costagliola C, Menzione M. Effect of vitamin E on the oxidative state of glutathione in plasma. Clin Physiol Biochem 1990;8:140-3.
107. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA 1990;87:4879-83.
108. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA 1991;88:1646-50.
109. Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. J Lipid Res 1992;33:385-97.
110. Konrad T, Vicini P, Kusterer K, et al. Alpha-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22:280-7.
111. Kocak G, Aktan F, Canbolat O, et al; ADIC Study Group - Antioxidants in Diabetes-Induced Complications. Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin-diabetes. Diabetes Nutr Metab 2000;13:308-18.
112. Midaoui AE, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens 2003;16:173-9.
113. Thirunavukkarasu V, Anuradha CV. Influence of alpha-lipoic acid on lipid peroxidation and antioxidant defence system in blood of insulin-resistant rats. Diabetes Obes Metab 2004;6:200-7.
114. Vasdev S, Gill V, Longerich L. Antihypertensive effect of alpha lipoic acid supplementation. Curr Top Nutraceut Res 2004;2:137-52.
115. Fulghesu AM, Ciampelli M, Muzj G, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril 2002;77:1128-35.
116. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr 1993;57:650-6.
117. Paolisso G, D'Amore A, Balbi V, et al. Plasma vitamin C affects glucose homeostasis in healthy subjects and in non-insulin-dependent diabetics. Am J Physiol 1994;266:E261-8. (Erratum in 1994;267[6 Pt 3]:Section E following table of contents, 1994:267[4 Pt 1]:Section E following table of contents).
118. Cabassi A, Dumont EC, Girouard H, et al. Effects of chronic N-acetylcysteine treatment on the actions of peroxynitrite on aortic vascular reactivity in hypertensive rats. J Hypertens 2001;19:1233-44.
119. Johnston CS, Meyer CG, Srilakshmi JC. Vitamin C elevates red blood cell glutathione in healthy adults. Am J Clin Nutr 1993;58:103-5.
120. Degenhardt TP, Alderson NL, Arrington D, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-50.
121. Hussein O, Radan A, Reuven V. Effect of cilazapril with or without low dose thiazide on LDL peroxidation in hypertensive patients. Am J Hypertens 2003;16:734-8.
122. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J. Benidipine, a long-acting calcium channel blocker, inhibits oxidative stress in polymorphonuclear cells in patients with essential hypertension. Hypertens Res 2005;28:107-12.
123. Suzuki O, Yoshida T, Tani S, et al. Antioxidative effects of benidipine hydrochloride in patients with hypertension independent of antihypertensive effects. Relationship between blood pressure and oxidative stress. Arzneimittelforschung 2004;54:505-12.
124. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004;15:251-8.
125. Martin A, Frei B. Both intracellular and extracellular vitamin C inhibit atherogenic modification of LDL by human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1997;17:1583-90.
126. Retsky KL, Freeman MW, Frei B. Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification. Anti- rather than prooxidant activity of vitamin C in the presence of transition metal ions. J Biol Chem 1993;268:1304-9.
127. Coombes JS, Powers SK, Hamilton KL, et al. Improved cardiac performance after ischemia in aged rats supplemented with vitamin E and alpha-lipoic acid. Am J Physiol Regul Integr Comp Physiol 2000;279:R2149-55.
128. Kunt T, Forst T, Wilhelm A, et al. Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clin Sci (Lond) 1999;96:75-82.
129. Kagan V, Serbinova E, Packer L. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem Biophys Res Commun 1990;169:851-7.
130. Hillstrom RJ, Yacapin-Ammons AK, Lynch SM. Vitamin C inhibits lipid oxidation in human HDL. J Nutr 2003;133:3047-51.
131. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001;38:606-11.
132. Atarashi K, Ishiyama A, Takagi M, et al. Vitamin E ameliorates the renal injury of Dahl salt-sensitive rats. Am J Hypertens 1997;10:116S-9S.
133. Ettarh RR, Odigie IP, Adigun SA. Vitamin C lowers blood pressure and alters vascular responsiveness in salt-induced hypertension. Can J Physiol Pharmacol 2002;80:1199-202.
134. Song D, Hutchings S, Pang CC. Chronic N-acetylcysteine prevents fructose-induced insulin resistance and hypertension in rats. Eur J Pharmacol 2005;508:205-10.
135. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats. Nutr Metab Cardiovasc Dis 2000;10:339-46.
136. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens 2000;567-73.
137. Vasdev S, Gill V, Longerich L, Parai S, Gadag V. Salt-induced hypertension in WKY rats: Prevention by alpha-lipoic acid supplementation. Mol Cell Biochem 2003;254:319-26.
138. Forde P, Scribner AW, Dial R, Loscalzo J, Troillet MR. Prevention of hypertension and renal dysfunction in Dahl rats by alpha-tocopherol. J Cardiovasc Pharmacol 2003;42:82-8.
139. Okamoto H, Kawaguchi H, Togashi H, Minami M, Saito H, Yasuda H. Effect of coenzyme Q10 on structural alterations in the renal membrane of stroke-prone spontaneously hypertensive rats. Biochem Med Metab Biol 1991;45:216-26.
140. Vasdev S, Gill V. Antioxidants in the treatment of hypertension. Int J Angiol 2005;14:60-73.
141. Newaz MA, Nawal NN. Effect of alpha-tocopherol on lipid peroxidation and total antioxidant status in spontaneously hypertensive rats. Am J Hypertens 1998;11:1480-5.
142. Girouard H, Chulak C, Lejossec M, Lamontagne D, de Champlain J. Chronic antioxidant treatment improves sympathetic functions and beta-adrenergic pathway in the spontaneously hypertensive rats. J Hypertens 2003;21:179-88.
143. Szczeklik A, Gryglewski RJ, Domagala B, Dworski R, Basista M. Dietary supplementation with vitamin E in hyperlipoproteinemias: Effects on plasma lipid peroxides, antioxidant activity, prostacyclin generation and platelet aggregability. Thromb Haemost 1985;54:425-30.
144. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: Effect of vitamin E. Am Heart J 1993;125:958-73.
145. Shih JC. Atherosclerosis in Japanese quail and the effect of lipoic acid. Fed Proc 1983;42:2494-7.
146. Parker RA, Sabrah T, Cap M, Gill BT. Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler Thromb Vasc Biol 1995;15:349-8.
147. Peluzio MC, Homem AP, Cesar GC, et al. Influences of alpha-tocopherol on cholesterol metabolism and fatty streak development in apolipoprotein E-deficient mice fed an atherogenic diet. Braz J Med Biol Res 2001;34:1539-45.
148. D'Uscio LV, Milstien S, Richardson D, Smith L, Katusic Z. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003;92:88-95.
149. Thurich T, Bereiter-Hahn J, Schneider M, Zimmer G. Cardioprotective effects of dihydrolipoic acid and tocopherol in right heart hypertrophy during oxidative stress. Arzneimittelforschung 1998;48:13-21.
150. Freyschuss A, Xiu RJ, Zhang J, et al. Vitamin C reduces cholesterol-induced microcirculatory changes in rabbits. Arterioscler Thromb Vasc Biol 1997;17:1178-84.
151. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: An exploratory study. Diabetes Res Clin Pract 2001;52:175-83.
152. Boshtam M, Rafiei M, Sadeghi K, Sarraf-Zadegan N. Vitamin E can reduce blood pressure in mild hypertensives. Int J Vitam Nutr Res 2002;72:309-14.
153. Duffy SJ, Gokce N, Holbrook M, et al. Treatment of hypertension with ascorbic acid. Lancet 1999;354:2048-9.
154. Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994;15(Suppl):S257-63.
155. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willer WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9.
156. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
157. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: The Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr 1996;64:190-6.
158. Loon E, Bosch J, Yusuf S, et al; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005;293:1338-47.
159. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.
160. Vasdev S, Gill V, Singal PK. Beneficial effect of low ethanol intake on the cardiovascular system. Possible biochemical mechansims. Vasc Health Risk Manag 2006;2:263-76.